Xvivo Perfusion AB (publ) (XVIVO.ST)
SEK 465.0
(1.97%)
SEK 465.0
(1.97%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 91.82 Million SEK | 398.29% |
| 2022 | 18.42 Million SEK | 126.04% |
| 2021 | 8.15 Million SEK | 118.64% |
| 2020 | -43.73 Million SEK | -985.5% |
| 2019 | 4.93 Million SEK | -61.06% |
| 2018 | 12.68 Million SEK | 102.64% |
| 2017 | 6.26 Million SEK | 317.06% |
| 2016 | 1.5 Million SEK | -70.75% |
| 2015 | 5.13 Million SEK | 37.27% |
| 2014 | 3.73 Million SEK | -53.59% |
| 2013 | 8.05 Million SEK | 1147.33% |
| 2012 | -769 Thousand SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 22.78 Million SEK | -66.72% |
| 2024 Q2 | 27.19 Million SEK | 19.35% |
| 2024 Q3 | 85.81 Million SEK | 215.58% |
| 2023 Q4 | 68.47 Million SEK | 2897.99% |
| 2023 Q3 | 2.28 Million SEK | -66.83% |
| 2023 Q1 | 14.17 Million SEK | 1831.34% |
| 2023 Q2 | 6.88 Million SEK | -51.42% |
| 2023 FY | 91.82 Million SEK | 398.29% |
| 2022 Q1 | 4.76 Million SEK | -60.91% |
| 2022 FY | 18.42 Million SEK | 126.04% |
| 2022 Q4 | 734 Thousand SEK | -86.4% |
| 2022 Q3 | 5.39 Million SEK | -28.31% |
| 2022 Q2 | 7.53 Million SEK | 58.03% |
| 2021 Q2 | -8.94 Million SEK | -248.2% |
| 2021 Q4 | 12.18 Million SEK | 1179.63% |
| 2021 Q3 | -1.12 Million SEK | 87.37% |
| 2021 FY | 8.15 Million SEK | 118.64% |
| 2021 Q1 | 6.03 Million SEK | 130.82% |
| 2020 FY | -43.73 Million SEK | -985.5% |
| 2020 Q2 | -16.01 Million SEK | -344.81% |
| 2020 Q3 | -14.68 Million SEK | 8.32% |
| 2020 Q4 | -19.57 Million SEK | -33.3% |
| 2020 Q1 | 6.54 Million SEK | 444.01% |
| 2019 Q1 | -315 Thousand SEK | -106.45% |
| 2019 FY | 4.93 Million SEK | -61.06% |
| 2019 Q3 | 4.92 Million SEK | 121.33% |
| 2019 Q4 | -1.9 Million SEK | -138.59% |
| 2019 Q2 | 2.22 Million SEK | 806.98% |
| 2018 Q1 | 3.8 Million SEK | -31.6% |
| 2018 FY | 12.68 Million SEK | 102.64% |
| 2018 Q4 | 4.88 Million SEK | 4834.34% |
| 2018 Q3 | 99 Thousand SEK | -97.46% |
| 2018 Q2 | 3.89 Million SEK | 2.29% |
| 2017 Q2 | 1.09 Million SEK | 2522.22% |
| 2017 Q1 | -45 Thousand SEK | 92.47% |
| 2017 FY | 6.26 Million SEK | 317.06% |
| 2017 Q4 | 5.56 Million SEK | 1685.75% |
| 2017 Q3 | -351 Thousand SEK | -132.2% |
| 2016 Q2 | 1.52 Million SEK | 36.45% |
| 2016 Q1 | 1.11 Million SEK | -70.26% |
| 2016 FY | 1.5 Million SEK | -70.75% |
| 2016 Q4 | -598 Thousand SEK | -11.78% |
| 2016 Q3 | -535 Thousand SEK | -135.2% |
| 2015 Q2 | 1.28 Million SEK | 225.44% |
| 2015 Q1 | -1.02 Million SEK | -227.56% |
| 2015 FY | 5.13 Million SEK | 37.27% |
| 2015 Q4 | 3.74 Million SEK | 232.98% |
| 2015 Q3 | 1.12 Million SEK | -12.25% |
| 2014 FY | 3.73 Million SEK | -53.59% |
| 2014 Q4 | -312 Thousand SEK | -121.12% |
| 2014 Q2 | 752 Thousand SEK | -58.7% |
| 2014 Q1 | 1.82 Million SEK | -22.97% |
| 2014 Q3 | 1.47 Million SEK | 96.41% |
| 2013 Q4 | 2.36 Million SEK | 50.0% |
| 2013 Q2 | 1.71 Million SEK | -28.63% |
| 2013 FY | 8.05 Million SEK | 1147.33% |
| 2013 Q1 | 2.4 Million SEK | 412.09% |
| 2013 Q3 | 1.57 Million SEK | -8.0% |
| 2012 Q4 | -769 Thousand SEK | 0.0% |
| 2012 FY | -769 Thousand SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.83 Million SEK | 217.961% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 11.285% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 11.285% |
| Arcoma AB | 2.56 Million SEK | -3481.123% |
| Bactiguard Holding AB (publ) | -138.38 Million SEK | 166.353% |
| BICO Group AB (publ) | -835.7 Million SEK | 110.987% |
| Boule Diagnostics AB (publ) | 24.97 Million SEK | -267.618% |
| CellaVision AB (publ) | 130.3 Million SEK | 29.537% |
| Clinical Laserthermia Systems AB (publ) | -79.79 Million SEK | 215.074% |
| Chordate Medical Holding AB (publ) | -29.18 Million SEK | 414.596% |
| C-Rad AB (publ) | 35.52 Million SEK | -158.437% |
| Duearity AB (publ) | -26.19 Million SEK | 450.592% |
| Dignitana AB (publ) | -17.36 Million SEK | 628.826% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 196.857% |
| Getinge AB (publ) | 2.41 Billion SEK | 96.193% |
| Scandinavian Real Heart AB (Publ) | -67.97 Million SEK | 235.075% |
| Iconovo AB (publ) | -45.89 Million SEK | 300.07% |
| Integrum AB (publ) | 4.03 Million SEK | -2177.012% |
| Luxbright AB (publ) | -25.37 Million SEK | 461.85% |
| Mentice AB (publ) | -2.81 Million SEK | 3359.496% |
| OssDsign AB (publ) | -130.49 Million SEK | 170.364% |
| Paxman AB (publ) | 8.33 Million SEK | -1002.281% |
| Promimic AB (publ) | -9.22 Million SEK | 1095.663% |
| Qlife Holding AB (publ) | -159.95 Million SEK | 157.403% |
| SciBase Holding AB (publ) | -55.58 Million SEK | 265.188% |
| ScandiDos AB (publ) | -14.64 Million SEK | 726.886% |
| Sectra AB (publ) | 428.38 Million SEK | 78.566% |
| Sedana Medical AB (publ) | -59.61 Million SEK | 254.029% |
| Senzime AB (publ) | -134.14 Million SEK | 168.446% |
| SpectraCure AB (publ) | -20.44 Million SEK | 549.195% |
| Stille AB | 26.64 Million SEK | -244.592% |
| Vitrolife AB (publ) | -3.85 Billion SEK | 102.384% |